Navigation Links
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
Date:6/16/2013

evelopment and Janssen Biotech are part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertake to update any forward-looking statements as a result of new informat
'/>"/>

SOURCE Janssen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
5. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
8. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... and BOSTON , September 16, ... Chief Scientific Officer, Fiona Marshall , will give a ... G protein-coupled receptors using StaR ®   ... Advances in Drug Discovery and Development " virtual symposium run ... Chemical Society. The virtual symposium is on Wednesday, 24 September ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare ... Espoo, Finland , have begun ... with ODM-201, an investigational oral androgen receptor inhibitor ... ODM-201 in men with castration-resistant prostate cancer who ... no detectable metastases. The trial is designed to ...
(Date:9/15/2014)... 15, 2014 GenomeDx Biosciences today announced ... American Society for Radiation Oncology (ASTRO) Annual Meeting ... Classifier, a genomic test capable of predicting aggressiveness ... improve patient outcomes for prostate cancer patients following ... recently published study that demonstrates how Decipher test ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3
... SILVER SPRING, Md., July 1, 2011 The ... Neohaler (indacaterol inhalation powder) for the long term, ... people with chronic obstructive pulmonary disease (COPD) including ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) COPD is a ...
... DUBLIN, July 1, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that it ... District of New Jersey against each,of Amneal Pharmaceuticals, LLC ... Shire,s VYVANSE,patents. The lawsuits were initiated in ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2
(Date:9/16/2014)... September 16, 2014 A recent ... used as a dermal filler, “Expression”, which has not ... on the market to be used as an intra-nasal ... FDA for use as a dermal filler. Because of ... off-label for wrinkle reduction, and patients have had bad ...
(Date:9/16/2014)... September 16, 2014 Dr. Eric Millstein ... of ACLsurgeryLA.com , a specialty website devoted to ... As an avid sports lover and athlete, Dr. Millstein ... and recovery from injuries to maintain active, healthy lifestyles. ... patients a resource dedicated specifically to ACL injuries ...
(Date:9/16/2014)... OXNARD, CA (PRWEB) September 16, 2014 ... Jivraj, founder of the Anacapa Dental Art Institute in ... Spectrum Day Vancouver conference this weekend. , Dr. Jivraj, ... about All-on-4™ dental implants in his presentation ... he will deliver at 12:40 p.m. Saturday, Sept. 20, ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
... radial head system employs the advantages of ... create the next generation of modular radial ... modular design, the implant system offers the ... patients anatomy. In addition, the capability of ...
For connection to the bipolar output of electrosurgical generators....
Recommended for use with spark gap coagulators for added safety. Also available in stainless steel (10-3002)....
Medicine Products: